OBJECTIVE: To assess the emergence of transmitted HIV-1 drug resistance (TDR) in Kampala, Uganda, 10 years after the scale-up of antiretroviral treatment (ART) and to compare with a previous survey among antenatal clinic attendees in 2007 (reporting 0% TDR). DESIGN: A cross-sectional survey was conducted among newly HIV-1 diagnosed, antiretroviral-naive young adults attending two large voluntary counseling and testing centers within the geographic area of Kampala. METHODS: Proxy criteria for recent HIV-1 infection were used as defined by the WHO. Population sequencing of the pol gene was performed on plasma samples with HIV-1 RNA at least 1000 copies/ml. Surveillance drug resistance mutations (SDRMs) were identified according to the 2009 WHO list for surveillance of TDR. HIV-1 subtypes were designated using maximum likelihood phylogenetic reconstruction. RESULTS: : Genotypic test results were obtained for 70 of 77 (90.9%) participants. SDRMs were identified in six samples yielding a prevalence of TDR of 8.6% (95% confidence interval 3.2-17.7%). Two had SDRMs to nucleoside reverse-transcriptase inhibitors (D67G and L210W), three had SDRMs to nonnucleoside reverse transcriptase inhibitors (G190A, G190S, and K101E), and one had SDRMs to protease inhibitors (N88D). Frequencies of HIV-1 subtypes were A (36/70, 51.4%), C ( two of 70; 2.9%), D (23/70, 32.9%), and unique recombinant forms (nine of 70, 12.9%). CONCLUSION: This repeated survey suggests an increase in TDR in Kampala, compared with a previous survey. This finding justifies increased vigilance with respect to surveillance of TDR in areas in Africa where ART programs are rolled-out.
OBJECTIVE: To assess the emergence of transmitted HIV-1 drug resistance (TDR) in Kampala, Uganda, 10 years after the scale-up of antiretroviral treatment (ART) and to compare with a previous survey among antenatal clinic attendees in 2007 (reporting 0% TDR). DESIGN: A cross-sectional survey was conducted among newly HIV-1 diagnosed, antiretroviral-naive young adults attending two large voluntary counseling and testing centers within the geographic area of Kampala. METHODS: Proxy criteria for recent HIV-1 infection were used as defined by the WHO. Population sequencing of the pol gene was performed on plasma samples with HIV-1 RNA at least 1000 copies/ml. Surveillance drug resistance mutations (SDRMs) were identified according to the 2009 WHO list for surveillance of TDR. HIV-1 subtypes were designated using maximum likelihood phylogenetic reconstruction. RESULTS: : Genotypic test results were obtained for 70 of 77 (90.9%) participants. SDRMs were identified in six samples yielding a prevalence of TDR of 8.6% (95% confidence interval 3.2-17.7%). Two had SDRMs to nucleoside reverse-transcriptase inhibitors (D67G and L210W), three had SDRMs to nonnucleoside reverse transcriptase inhibitors (G190A, G190S, and K101E), and one had SDRMs to protease inhibitors (N88D). Frequencies of HIV-1 subtypes were A (36/70, 51.4%), C ( two of 70; 2.9%), D (23/70, 32.9%), and unique recombinant forms (nine of 70, 12.9%). CONCLUSION: This repeated survey suggests an increase in TDR in Kampala, compared with a previous survey. This finding justifies increased vigilance with respect to surveillance of TDR in areas in Africa where ART programs are rolled-out.
Authors: Steven J Reynolds; Oliver Laeyendecker; Gertrude Nakigozi; Joel E Gallant; Wei Huang; Sarah E Hudelson; Thomas C Quinn; Kevin Newell; David Serwadda; Ronald H Gray; Maria J Wawer; Susan H Eshleman Journal: AIDS Res Hum Retroviruses Date: 2012-04-26 Impact factor: 2.205
Authors: Guinevere Q Lee; Suzanne McCluskey; Yap Boum; Peter W Hunt; Jeffrey N Martin; David R Bangsberg; Xiaojiang Gao; P Richard Harrigan; Jessica E Haberer; Mark J Siedner Journal: J Acquir Immune Defic Syndr Date: 2017-10-01 Impact factor: 3.731
Authors: Steven J Reynolds; Victor Ssempijja; Ronald Galiwango; Anthony Ndyanabo; Gertrude Nakigozi; Fred Lyagoba; Jamirah Nazziwa; Andrew Redd; Susanna L Lamers; Ron Gray; Maria Wawer; David Serwadda; Thomas C Quinn Journal: AIDS Res Hum Retroviruses Date: 2016-11-28 Impact factor: 2.205
Authors: Suzanne M McCluskey; Guinevere Q Lee; Kimia Kamelian; Annet Kembabazi; Nicholas Musinguzi; Mwebesa B Bwana; Conrad Muzoora; Jessica E Haberer; Peter W Hunt; Jeffrey N Martin; Yap Boum; David R Bangsberg; P Richard Harrigan; Mark J Siedner Journal: AIDS Patient Care STDS Date: 2018-07 Impact factor: 5.078
Authors: Julie E Myers; Barbara S Taylor; Rita A Rojas Fermín; Emily Virginia Reyes; Catherine Vaughan; Lina José; Carmen Javier; Ramona Franco Estévez; Yeycy Donastorg Cabral; Arelis Batista; Yolanda Lie; Eoin Coakley; Scott M Hammer; Karen Brudney Journal: AIDS Res Hum Retroviruses Date: 2011-09-23 Impact factor: 2.205
Authors: G M Hunt; J Ledwaba; A E Basson; J Moyes; C Cohen; B Singh; S Bertagnolio; M R Jordan; A Puren; L Morris Journal: Clin Infect Dis Date: 2012-05 Impact factor: 9.079
Authors: Gert U van Zyl; Lisa M Frenkel; Michael H Chung; Wolfgang Preiser; John W Mellors; Jean B Nachega Journal: AIDS Date: 2014-11-28 Impact factor: 4.177
Authors: Amin S Hassan; Shalton M Mwaringa; Clare A Obonyo; Helen M Nabwera; Eduard J Sanders; Tobias F Rinke de Wit; Patricia A Cane; James A Berkley Journal: AIDS Res Hum Retroviruses Date: 2012-09-11 Impact factor: 2.205
Authors: Guinevere Q Lee; David R Bangsberg; Conrad Muzoora; Yap Boum; Jessica H Oyugi; Nneka Emenyonu; John Bennett; Peter W Hunt; David Knapp; Chanson J Brumme; P Richard Harrigan; Jeffrey N Martin Journal: AIDS Res Hum Retroviruses Date: 2014-07-29 Impact factor: 2.205
Authors: Godwin E Imade; Atiene S Sagay; Beth Chaplin; Philippe Chebu; Jonah Musa; Jonathan Okpokwu; Donald J Hamel; Ishaya C Pam; Oche Agbaji; Jay Samuels; Seema Meloni; Jean-Louis Sankale; Prosper Okonkwo; Phyllis Kanki Journal: AIDS Res Hum Retroviruses Date: 2013-11-22 Impact factor: 2.205